Pfizer completes Metsera acquisition in deal worth up to $10 bn / Photo: ANGELA WEISS - AFP/File
-
MLS to align calendar with world's top football leagues
-
BBC says sorry to Trump, but rejects defamation claim
-
Mbappe, Olise star as France seal spot at 2026 World Cup
-
Ronaldo sent off as Ireland stun Portugal in World Cup qualifier
-
England cruise against Serbia with Bellingham reduced to cameo role
-
Osimhen strikes twice as Nigeria set up World Cup clash with DR Congo
-
Alcaraz beats Sinner to year-end world number one after defeating Musetti at ATP Finals
-
25 oil-supplying states accused of 'complicity' in Gaza war
-
Eagles aim to keep rolling despite Brown turmoil
-
Alcaraz to end year as world number one after seeing off Musetti at ATP Finals
-
Schmidt eager for fan's eye view before last Dublin clash as Wallabies boss
-
'My whole life is here': migrants in Chile fear far-right rule
-
Strong first-half profits keep Alstom firmly on rails
-
'Like a horror movie': 770 km of fear for those fleeing Sudan's El-Fasher
-
Pfizer completes Metsera acquisition in deal worth up to $10 bn
-
Boeing union votes to end strike, accept new contract
-
Farrell says Hansen 'ready and able' to step-in at full-back for Ireland
-
Osimhen strikes twice as Nigeria keep World Cup hopes alive
-
Bad Bunny in box seat as Latin Grammys hit Vegas
-
We need to talk about our fossil fuel addiction: UNEP chief
-
Wales boss Tandy 'excited' to see Rees-Zammit start against Japan
-
UK artist turns 'money for old rope' into £1m art exhibition
-
Nagelsmann backs Woltemade to shine for injury-hit Germany
-
Zelensky sanctions associate as fraud scandal rocks Ukraine
-
Starbucks baristas launch strike on chain's 'Red Cup Day'
-
Fiji unchanged for France Autumn Nations Series trip
-
All Blacks boss Robertson at ease with 'respectful' England challenge to haka
-
Stocks on the slide despite end of US shutdown
-
Church bells ring as France marks decade since Paris attacks
-
France scrum-half Serin commits for two more seasons to Toulon
-
Starlink, utilised by Myanmar scam centres, sees usage fall nationwide
-
YouTube superstar MrBeast opens pop-up park in Saudi Arabia
-
'Black Klimt' steps out of shadows and into political tug-of-war
-
Study flags 'complicity' of oil-supplying states in Gaza war
-
US shutdown scorecard: Who cashed in, who crashed out
-
'Bleak' future for seals decimated by bird flu, scientists warn
-
Australia turn to O'Connor in search of Ireland inspiration
-
Mexican car industry fears higher tariffs on China will drive its demise
-
Battle brews over Australia or Turkey hosting next COP
-
Hansen and Prendergast start for Ireland against Australia
-
McIlroy two shots off the lead as Kim top after round one in Dubai
-
Stocks sluggish as US government shutdown ends
-
De Minaur knocks out Fritz to keep ATP Finals hopes alive
-
Ikitau and O'Connor return as Wallabies make changes for Ireland
-
EU backs small parcel duties to tackle China import flood
-
Europe court orders Poland pay damages to woman who aborted abroad
-
EU lawmakers back proxy voting for pregnant women, new mothers
-
England great Anderson to play on for Lancashire
-
Swiss economy minister back in Washington for tariff talks
-
Race for first private space station heats up as NASA set to retire ISS
NYSE - LSE
Pfizer completes Metsera acquisition in deal worth up to $10 bn
US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.
The approval from Metsera's shareholders opens the door for Pfizer to make inroads into the fast-growing market for weight loss drugs.
Metsera, a US company specializing in obesity treatments, had been the subject of escalating offers from Pfizer and Danish challenger Novo Nordisk, which makes the weight loss drug Wegovy and Ozempic, a diabetes medication with weight loss benefits.
Pfizer said in a statement that its acquisition was successfully completed.
It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.
This involved $65.60 per share in cash, and an additional $20.65 per share linked to the success of its drug pipeline.
"By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it," said Pfizer chief executive Albert Bourla.
"We look forward to combining Metsera's innovative portfolio with our global development, manufacturing and commercial infrastructure," he added.
The potential sale of Metsera to Novo Nordisk had drawn scrutiny over potential antitrust implications.
F.Dubois--AMWN